COMP <GO>
PBH vs PHVS // EV/EBITDA & P/E VALUATION
Prestige Consumer Healthcare Inc. (NYSE) VS. Pharvaris N.V. (NASDAQ) • 15-METRIC TALLY: PBH 0
— PHVS 2
■ METRIC PARITY
LAST: $48.75 (+2.01%) • MKT CAP: $2.31B
valuation
7.0x
LAST: $33.58 (+2.32%) • MKT CAP: $2.34B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. PHVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBH | PHVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 10.67% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 28.40% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 17.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -4.30% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.1 | 59.6 | -5.43 | PHVS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.31B | $2.34B | -$29.9M | PHVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBH REV | PHVS REV | PBH GROSS % | PHVS GROSS % | PBH FCF | PHVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.09B | — | 54.7% | — | $246.4M | — |
| FY 2024 | $1.14B | — | 55.8% | — | $243.3M | — |
| FY 2023 | $1.13B | — | — | — | $248.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
PHVS // BETA —